#### Lehigh Valley Health Network LVHN Scholarly Works

Department of Family Medicine

#### Diabetes Pathophysiology and Treatment Strategies

Beth Careyva MD Lehigh Valley Health Network, beth a.careyva@lvhn.org

Follow this and additional works at: http://scholarlyworks.lvhn.org/family-medicine Part of the <u>Medical Specialties Commons</u>

#### Published In/Presented At

Careyva, B. (2014, October, 31). *Diabetes Pathophysiology and Treatment Strategies*. Lecture presented at: Lehigh University for BioScience in the 21st Century Course, http://www.lehigh.edu/~inbios21/resources.html, Bethlehem, PA.

This Presentation is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion in LVHN Scholarly Works by an authorized administrator. For more information, please contact LibraryServices@lvhn.org.

# Diabetes: Pathophysiology and Treatment Strategies

Beth Careyva, M.D. October 31, 2014 Lehigh University Bioscience in the 21<sup>st</sup> Century

# Objectives

- Review the epidemiology and trends of diabetes
- Discuss the pathophysiology of diabetes
- Delineate treatment strategies including lifestyle modification and medications

# Epidemiology

- 11.3% of those over the age of 20 living with DM2 in the US<sup>1</sup>
- World Health Organization estimates 7<sup>th</sup> leading cause of death by 2030<sup>2</sup>
- More than \$300 billion spent on diabetes-related medical costs in 2012<sup>3</sup>

 Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011.
World Health Organization. Diabetes Fact Sheet No. 312. Reviewed October 2013.
www.who.int/mediacentre/factsheets/fs312/en/. Accessed May 9, 2014.
American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care

2013;36:1033-1046.

#### **CDC Fact Sheet**

#### National Diabetes Fact Sheet, 2011



#### FAST FACTS ON DIABETES

Diabetes affects 25.8 million people 8.3% of the U.S. population

> DIAGNOSED 18.8 million people


UNDIAGNOSED 7.0 million people


All ages, 2010

- Among U.S. residents aged 65 years and older, 10.9 million, or 26.9%, had diabetes in 2010.
- About 215,000 people younger than 20 years had diabetes (type 1 or type 2) in the United States in 2010.
- About 1.9 million people aged 20 years or older were newly diagnosed with diabetes in 2010 in the United States.

# DM2 Epidemiology


90% of those with diabetes in the US, Canada, and Europe have type 2 diabetes





#### Trends in Prevalence and Control of Diabetes in the United States, 1988–1994 and 1999–2010

Elizabeth Selvin, PhD, MPH; Christina M. Parrinello, MPH; David B. Sacks, MB, ChB; and Josef Coresh, MD, PhD



Data from U.S. adults aged  $\geq 20$  y in NHANES 1988–1994, 1999–2004, and 2005–2010. Total confirmed diabetes was defined as diagnosed diabetes or undiagnosed diabetes with diagnostic levels of both hemoglobin A<sub>1c</sub> ( $\geq 6.5\%$ ) and fasting glucose (7.0 mmol/L [ $\geq 126$  mg/dL]). Obesity was defined as body mass index  $\geq 30$  kg/m<sup>2</sup>; 601 persons were missing body mass index data. Prevalence estimates for total confirmed diabetes and obesity were obtained using only the subsample of participants who attended the morning fasting session (7385 participants for 1988–1994, 5680 participants for 1999–2004, and 6719 participants for 2005–2010). The midpoint for obesity prevalence between 1988–1994 and 1999–2004 was calculated as the average of the prevalence of the 2 periods. NHANES = National Health and Nutrition Examination Survey. The Lancet Diabetes & Endocrinology, Volume 2, Issue 1, Pages 56 - 64, January 2014 doi:10.1016/S2213-8587(13)70112-8 Cite or Link Using DOI < Previous Article | Next Article >

Published Online: 03 December 2013

Copyright © 2014 Elsevier Ltd All rights reserved.

#### Diabetes: a 21st century challenge

Prof Paul Z Zimmet MD a 🗹 , Prof Dianna J Magliano PhD a, Prof William H Herman MD b, Prof Jonathan E Shaw MD a

- Number of people with diabetes has more than doubled in the past 20 years
- Concerning is the number of new diagnoses in children and adolescents
- Need to work on prevention with focus on social and environmental factors

#### What is diabetes?



#### **Definition of Diabetes**

- Group of diseases resulting in elevated blood glucose levels
- Involves insufficient insulin or decreased response to insulin resulting in elevated blood glucose
- Glucose is the energy source for the cells

www.mayoclinic.org/diseases-conditions/diabetes/basics/definitions

### **Types of Diabetes**


- Type 1 Diabetes (DM1)
- Type 2 Diabetes (DM2)
- Prediabetes
- Gestational Diabetes

### DM1

- Autoimmune destruction of insulin producing beta cells in pancreas
- Insulin dependent
- Typically childhood onset
- 5 10% of diabetes worldwide



dtc.ucsf.edu



Time course of the development of type 1 diabetes. Genetic markers are present from birth, immune markers first appear at the time of the environmental triggering events, and sensitive metabolic markers of deficient insulin secretion begin to appear soon after the onset of betacell dysfunction. However, clinically evident type 1 diabetes does not occur until there has been a much greater loss of functioning beta-cell mass.

Date

#### **Diabetes Before Insulin**

Diabetes, from the Greek word meaning "to pass through" or "pipe-like" has been claiming lives for thousands of years. A diabetic's body is unable to utilize food's nutrients as energy, causing extra sugar to collect in blood and urine (Bliss 20). Food simply "passes through" the body, without absorbing any nutrients.

#### **Previous Treatments:**

-Egyptians treated diabetes "with a combination of ground earth, water, bones, wheat, and lead" (Yuwiler 15)

-In the nineteenth century, physicians tried other common healing practices, such as bleeding, cupping or blistering patients.

-In the nineteenth and twentieth centuries, "opium seemed to reduce the despair of dying [diabetic] patients" (Yuwiler 16)



Eleventh century physician who searched for treatment. (Yuwiler 16)


#### Slim Chances



With no effective treatment aside from a semi-starvation diet, a diabetic's outlook appeared grim. Before 1922, diabetic children rarely lived a year after diagnosis, five percent of adults died within two years, and less than 20 percent lived more than ten (Berger 57). Untreated diabetics faced blindness, loss of limbs, kidney failure, stroke, heart attack and death (Yuwiler 12).


http://www.trumanlibrary.org/histday/insulin/diabetes-before-insulin.html

#### Nobel Prize in 1923



#### Insulin

- Hormone that regulates the amount of glucose in the blood
- Produced by beta cells in pancreas
- Beta cells release insulin with each meal to help the body use or store glucose



#### Prediabetes

- Impaired fasting glucose or impaired glucose tolerance
- Increased risk for developing DM2
- Annual screening for diabetes recommended
- Intensive lifestyle modifications recommended

#### DM2

- Inadequate insulin production OR
- Insulin resistance OR
- Inadequate insulin production AND insulin resistance

#### Linked to obesity

 Increased risk if African, Asian, Native American, Latino, or Pacific Islander

#### **Gestational DM**

- Increased risk if overweight or obese prior to pregnancy
- Affects 2 10% of women during pregnancy
- Increases risk of DM2

### Summary

- Diabetes increasing in prevalence
- 4 Types: DM1, DM2, Prediabetes, and Gestational Diabetes
- Increased prevalence linked to obesity and environmental factors

# Questions?

# Pathophysiology

# Pathophysiology

- 1. Impaired Insulin Secretion
- 2. Hyperglycemia
- 3. Insulin Resistance

#### Metabolic Defects

- Decreased glucose transport and utilization at the level of the muscle and adipose tissue
- Increased glucose production by the liver
- Decreased insulin secretion by the pancreas


#### What organs are involved?

- Pancreas: beta cells secrete insulin and amylin, alpha cells secrete glucagon
- GI Tract: secrete GLP-1 to signal beta cells to increase insulin and alpha cells to decrease glucagon
- Liver: stores glucose as glycogen, supplies glucose via glyconeogenesis and gluconeogenesis
- Muscles and adipose tissue: remove glucose from the blood
- Adrenal glands: secrete epinephrine and cortisol

### **Insulin Secretion**

- From beta cells in pancreas
- Decreases over time in DM2
- May be exacerbated by hyperglycemia


#### Alpha and Beta Cells in Pancreas




dtc.ucsf.edu

### **Insulin Resistance**

- Likely genetic component
- Exacerbated by inflammatory particles secreted by adipose tissue (leptin adiponectin, tumor necrosis factor alpha, and resistin)








dtc.ucsf.edu

### Insulin and Glucagon



## Glucagon

- Produced by alpha cells in pancreas
- Serves as counterbalance to insulin
- Signal liver to initiate glyconeogenesis
- In DM, glucagon levels rise inappropriately after eating




Fasting State


dtc.ucsf.edu

## GLP-1


- Released from gut
- Signal beta cells to increase insulin and decrease glucagon



# **Epinephrine and Cortisol**



dtc.ucsf.edu




Fasting State


dtc.ucsf.edu

### GLP-1

- Released from gut
- Signal beta cells to increase insulin and decrease glucagon



### **Epinephrine and Cortisol**



dtc.ucsf.edu

### What organs are involved?

- Pancreas: beta cells secrete insulin and amylin, alpha cells secrete glucagon
- GI Tract: secrete GLP-1 to signal beta cells to increase insulin and alpha cells to decrease glucagon
- Liver: stores glucose as glycogen, supplies glucose via glyconeogenesis and gluconeogenesis
- Muscles and adipose tissue: remove glucose from the blood
- Adrenal glands: secrete epineprhine and cortisol

### **Genetic Causes**

- Lifetime risk of DM2 is 5-10 times higher in first-degree relatives
- Increased prevalence in certain ethnic groups, including people of Hispanic, African, and Asian decent

### **Environmental Causes**

- Food sources
- Activity levels
- Built environment



### Socioecological Determinants of Prediabetes and Type 2 Diabetes: Agenda for Action

Tiffany L. Gary-Webb, PhD, MHS, Aida L. Maisonet Giachello, PhD, Krista Maier, JD, and Heather Skrabak

- Need to recognize implications of built, food, school, and work environments
- Greater impact on groups with lower socioeconomic status

### Summary

- Diabetes is the resultant hyperglycemia from inadequate insulin secretion, insulin resistance, or both
- It is progressive, with continual beta cell decline over time
- Genetic and environmental factors also play a role

# Questions?

## TREATMENT STRATEGIES

### Goal

 Approach normoglycemia for most patients to decrease risk of microvascular and macrovascular complications

### **Treatment Strategies**


- 1. Lifestyle modifications: weight loss, dietary changes, increased physical activity
- 2. Self-monitoring
- **3.** Medications: oral medications, injectable non-insulin medications, insulin
- 4. Screening for and preventing complications

### Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach

Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

 Tailored approach to treatment based on age, comorbidities, and availability of resources

### Depiction of the elements of decision making used to determine appropriate efforts to achieve glycemic targets.






### Lifestyle Modifications

- Low carbohydrate diets
- Increased physical activity
- Weight loss
- Bariatric surgery

### **Bariatric surgery**

- Patients followed for 15 years after surgery
- Associated with increased likelihood of long-term remission and decreased rates of microvascular and macrovascular complications

Sjostrom L, Peltonen M, Jacobson P, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA 2014;311(22):2297-2304.




### **Diabetes Super Foods**


- Beans
- Green leafy vegetables
- Sweet potatoes
- Berries
- Fish rich in omega 3 Fatty acids
- Fat-free milk and yogurt
- Whole grains
- Tomatoes
- Citrus fruits











It's not that diabetes, heart disease and obesity runs in your family. It's that no one runs in your family.

someecards

### **DM Management**

- Requires patient-activation and patient-clinician partnerships
- Gradual decline of beta cell function over time warrants changes to the care plan

### Self-management


- Dietary changes
- Monitoring and recording blood glucose
- Keeping a log book of glucose readings
- Regular foot checks
- Laboratory tests

### Hemoglobin A1c

- Glucose attaches to hemoglobin -> glycosylated hemoglobin
- Provides estimate of average glucose over the past 3 months
- May not be accurate if hemoglobin mutation

### Medications

Percentage of adults with diagnosed diabetes receiving treatment with insulin or oral medication, United States, 2007–2009



■Insulin only ■Insulin and oral medication ■Oral medication only ■No medication

Source: 2007–2009 National Health Interview Survey.

### Metformin

- First line oral agent
- Decreases hepatic glucose production
- Insulin sensitizer
- Shown to decrease mortality

### Sulfonylureas

- Bind to component of ATP-dependent potassium channel in pancreatic beta cell (sulfonylurea 1 receptor)
- Stimulate insulin secretion from the pancreas
- Include glipizide, glyburide, gliclazide, and glimepiride

### Incretin Based Therapies (DPP-4 Inhibitors, GLP-1 Agonist)

- DPP-4 inhibitors result in increased GLP-1
- GLP-1 is produced by small intestines in response to food
- GLP-1 Agonists bind to GLP-1 receptors and stimulate insulin release
- Both mechanisms achieve same goal of glucose-dependent insulin release from pancreas



### Thiazolidinediones

- Increase insulin sensitivity to remove glucose from the blood stream
- Act on muscles, adipose tissue, and the liver to increase glucose use and decrease glucose production
- Mechanism not fully understood
- Bind to peroxisome proliferator-activated receptors to regulate gene expression

### Insulin

- Secreted with meals and in a pulsatile manner for basal level
- ~50% of insulin secretion is basal with the remaining being secreted around meals



### Types of Insulin

- Rapid-acting
- Regular or Short-acting
- Intermediate-acting
- Long-acting

### Modes of Insulin Administration

- Injection from insulin in bottle
- Injection from insulin pen
- Insulin pumps
  - More flexibility in dosing
  - Fewer highs and lows

### Why is insulin not a pill?

- Insulin would be inactivated in the digestive system
- Needs to be injected to enter bloodstream

### Summary

- Most effective treatment strategies combine lifestyle changes, self-care, medications, and prevention of complications
- Most patients will eventually require insulin given progressive nature of the disease

## How has treatment changed in the 21<sup>st</sup> century?

- Creation of additional oral medications
- More sophisticated insulin pumps
- Increased use of bariatric surgery
- Technology support for self management (telehealth, patient portals)

### Innovations in Technology




Glooko's mobile, cloud based diabetes management system serves patients, providers & payers by syncing blood glucose data from <u>30+ meters to Apple & Android devices</u>, facilitating patient lifestyle data aggregation, and layering on smart analytics for diabetes population management.

Glooko.com

### More to come...

- Genetic testing to identify predisposition and which medications will be most effective
- New oral and injectable medications
- Health policy for prevention
- More pancreas transplants?

### Institute for Healthcare Improvement Triple Aim



http://www.ihi.org/Engage/Initiatives/TripleAim/Pages/default.aspx

### References

- 1. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011.
- 2. World Health Organization. Diabetes Fact Sheet No. 312. Reviewed October 2013. www.who.int/mediacentre/factsheets/fs312/en/. Accessed May 9, 2014.
- 3. American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013;36:1033-1046.
- 4. Zimmet PZ, Magliano DJ, Herman WH, et al. Diabetes: A 21<sup>st</sup> Century Challenge. Lancet Diabetes Endocrinol. 2013;2(1):56-64.
- 5. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: A patient-centered approach. Diabetes Care.2012;35(6):1364-1379.
- 6. Selvin E, Parrinello CM, Sacks DB, Coresh J. Trends in prevalence and control of diabetes in the United States, 1988-1994 and 1999-2010. Ann Intern Med. 2014;160:517-525.
- 7. Gary-Webb TL, Maisonet Giachello AL, Maier K, et al. Socioecological determinants of prediabetes and type 2 diabetes: agenda for action. Clin Diabetes.2014;32(3): 140-143.

### With Gratitude

Dr. Lowe-Krentz

Dr. Ware



# Questions?